Tuberculosis in patientes treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?

Tumor necrosis factor alpha antagonists (TNFA) are biological agents to treat chronic inflammatory and autoimmune diseases. However, their use is associated with an increased rate of tuberculosis, endemic mycoses, and intracellular bacterial infections. Since tuberculosis is moderately to highly end...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2007

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/23535

Acceso en línea:

https://repository.urosario.edu.co/handle/10336/23535

Palabra clave:

Bacteria (microorganisms)
Antiinflammatory agent
Monoclonal antibody
Tumor necrosis factor alpha
Adult
Aged
Article
Autoimmune disease
Case report
Colombia
Drug antagonism
Female
Human
Immunology
Male
Middle aged
Risk assessment
Risk factor
Tuberculosis
Adult
Aged
Anti-Inflammatory Agents
Autoimmune Diseases
Colombia
Female
Humans
Male
Middle Aged
Risk Assessment
Risk Factors
Tuberculosis
Tumor Necrosis Factor-alpha
Colombia
Endemic diseases
Tuberculosis
Tumor necrosis factor-alpha/immunology
Monoclonal
Antibodies

Rights

License

Abierto (Texto Completo)